GSK plc
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), GSK plc reported 13 stock positions worth $602.2 million. Its top holding was Crispr Therapeutics (CRSP) at 29.2% of the portfolio, followed by Wave Life Sciences (WVE, 17.6%) and Vir Biotechnology (VIR, 14.5%). Its holdings were unchanged from Q1 2026.
- Most Recent 13F
- Q2 2026
- Location
- London, X0
- CIK
- 0001131399
- Portfolio Value
- $602.2M (Q2 2026)
- SEC Filing
- 0001999371-26-017873 ↗ filed Aug 13, 2026
Holdings Value
Holdings 13 stocks · $602.2M
| CRSP Crispr Therapeutics AG | 29.17% | 3,220,627 | $175.7M | No change |
| WVE Wave Life Sciences Ltd. | 17.60% | 18,245,691 | $106.0M | No change |
| VIR Vir Biotechnology Inc. | 14.47% | 8,550,954 | $87.1M | No change |
| BNTX Biontech SE-ADR | 13.75% | 889,824 | $82.8M | No change |
| IDYA Ideaya Biosciences Inc. | 8.25% | 1,333,333 | $49.7M | No change |
| CYTK Cytokinetics Inc. | 4.82% | 340,434 | $29.0M | No change |
| LYEL Lyell Immunopharma Inc. | 3.53% | 1,512,659 | $21.3M | No change |
| SPRO Spero Therapeutics Inc. | 3.37% | 9,190,606 | $20.3M | No change |
| NKTX Nkarta Inc. | 1.48% | 3,150,732 | $8.9M | No change |
| FULC Fulcrum Therapeutics Inc. | 1.09% | 1,785,714 | $6.5M | No change |
| BCYC Bicycle Therapeutics PLC-ADR | 1.08% | 1,529,561 | $6.5M | No change |
| CVRX CVRX Inc. | 0.86% | 1,007,583 | $5.2M | No change |
| RGNX Regenxbio Inc. | 0.54% | 271,456 | $3.3M | No change |
Portfolio Sells Q1 2026 → Q2 2026
| None this quarter. | |||
Portfolio Buys Q1 2026 → Q2 2026
| None this quarter. | |||